94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
METHODS article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1545549
This article is part of the Research TopicAchilles Heel of CAR T-Cell TherapyView all 9 articles
Engineering safe anti-CD19-CD28ζ CAR T cells with CD8α hinge domain in serum-free media for adoptive immunotherapy
Provisionally accepted
Muthuganesh Muthuvel1
Thamizhselvi Ganapathy2
Trent Spencer3
Sunil S. Raikar3Saravanabhavan Thangavel3
Alok Srivastava4
Sunil Martin1*- 1Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India
- 2Center for Stem Cell Research (CSCR), Vellore, Tamil Nadu, India
- 3Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta, Colorado, United States
- 4St. John’s Medical College Hospital, Bangalore, Karnataka, India
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Despite the curative potential, high cost of manufacturing and the toxicities limits the wider access of Chimeric Antigen Receptor (CAR) T cell therapy in global medicine. CARs are modular synthetic antigen receptors integrating the single-chain variable fragment (scFv) of an immunoglobulin molecule to the TCR signaling. CARs allow HLA independent, T cell mediated destruction of tumor cells independent of tumor associated-HLA downregulation and survive within the patient as 'living drug.' Here we describe an indigenous protocol for the development of an αβ CAR T cell targeting CD19; a pan B cell malignancy antigen and tested the antitumor functions against relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in vitro.
Keywords: CD19 CAR T cells, B lineage malignancies, Serum free media, SIN Vector, NALM-6
Received: 15 Dec 2024; Accepted: 08 Apr 2025.
Copyright: © 2025 Muthuvel, Ganapathy, Spencer, Raikar, Thangavel, Srivastava and Martin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Sunil Martin, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.